
Autonomix Medical fell 94.5% from $19.95 to $1.09, behind the S&P 500's +10.6%. Its worst day was Aug 5 (−37.9%), and its low came Nov 17 at $1.08.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Autonomix Medical closed at its highest level of the year, 14.7% above where the year started.
+6.9% · S&P 500 +1.5%
EPS of $-7.56 missed the $-4.41 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−1.7% · S&P 500 −1.5%
EPS of $1.89 beat the $-0.26 estimate on $0.00 revenue.
−0.6% · S&P 500 +0.6%
The patent expands the Company’s intellectual property protection for technologies designed to sense, map and selectively target nerves associated with tumors, cancer-related pain, organ function and other autonomic
+434.2%, the year's best day, on 120M shares, the year's heaviest volume · S&P 500 +1.8%
EPS of $-5.02 beat the $-6.41 estimate on $0.00 revenue.
−9.0% · S&P 500 +0.7%
EPS of $-2.51 beat the $-2.62 estimate on $0.00 revenue.
+8.8% · S&P 500 −0.4%
Where it ended: a close of $1.09 on Nov 18, 2026. Up next: Q3 2027 earnings on Feb 10, 2027 (EPS est. $-1.64).
Nothing in the past 12 months.
All AMIX dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AMIX and SPY from Benzinga historical bars. Not investment advice.